Cellular dormancy in minimal residual disease following targeted therapy

Area of Science:

• Oncology
• Cancer Biology
• Translational Research

Background:

• Breast cancer mortality is primarily linked to tumor recurrence after remission.
• The biology of residual tumor cells causing late recurrence remains poorly understood.
• Identifying properties of these cells is crucial for preventing recurrence and improving outcomes.

Purpose of the Study:

• To investigate the biological characteristics of residual tumor cells.
• To understand the mechanisms of tumor recurrence after therapy.
• To identify potential therapeutic targets for preventing breast cancer relapse.

Main Methods:

• Utilized inducible transgenic mouse models (HER2/neu, Wnt1) and human breast cancer xenografts.
• Employed fluorescence-activated cell sorting to isolate tumor cells from primary, residual, and recurrent tumors.
• Analyzed gene expression signatures and tumor-initiating cell properties.

Main Results:

• Residual tumor cells survive oncogenic pathway inhibition and enter a dormant state.
• Dormant cells retain the ability to cause recurrence after extended latency.
• Dormant cells exhibit unique conserved features and a gene signature linked to recurrence-free survival.
• Tumor-initiating cells responsible for recurrence may differ from those driving primary tumors.

Conclusions:

• Residual cancer cells survive therapy in a dormant state within a specific microenvironment.
• Dormancy appears to be a conserved response to targeted therapy.
• Mechanisms of dormancy at local and distant sites may be related.
• The dormant state presents a potential therapeutic target to prevent cancer recurrence.